The results of a cohort of 58 patients treated with PD-1/PD-L1 inhibitors revealed that NSCLCs harboring EGFR mutations are associated with poor response, and such mutations were speculated to be associated with low rates of concurrent PD-L1 expression and CD8+ T cells within the tumor microenvironment (19). This evidence concerns the gene PDCD1 and neoplasm.